Plexitome Anterior Stromal Puncture Now Available Through VEO Ophthalmics
Plexitome Medical announced the launch of Plexitome, a new device designed to transform the treatment of Recurrent Corneal Erosion (RCE) and epithelial basement membrane dystrophies (EBMD). Plexitome is being introduced to the market through a strategic partnership with VEO Ophthalmics.
Anterior stromal puncture (ASP) has long been a therapeutic option for recurrent corneal conditions, but manual techniques often present challenges in consistency and predictability. Plexitome is designed to address these limitations with a 6.2 mm diameter disc array housing approximately 675 precisely engineered micro-spikes. This design enables controlled, uniform puncture depth through Bowman’s layer—without creating optically significant anterior stromal scarring.
According to Plexitome Medical, by allowing up to 3,375 individual epithelial attachment points across five imprints, Plexitome strengthens corneal healing, enhances patient outcomes, and helps reduce long-term recurrence rates.
“Plexitome represents a significant step forward in the management of corneal disorders, particularly in the optical axis,” said Edward Chaum, MD, PhD, Founder and Chief Medical Officer at Plexitome Medical. “The device was engineered to improve outcomes while eliminating the unpredictability and limitations of manual ASP. VEO Ophthalmics has a history of bringing innovative products to market, and we are excited to partner with them for our commercialization strategy.”
According to a company news release, in real-world clinical use, Plexitome has demonstrated:
Effective penetration of Bowman’s layer through both debrided and loose, intact epithelium
Creation of stable epithelial attachments even in areas where traditional ASP methods often fail
Potential to shorten healing times for large corneal abrasions
Reduced risk of recurrence in erosive conditions
Under the new partnership, VEO Ophthalmics will lead the commercial introduction of Plexitome, providing ophthalmologists and surgical teams with product access, training, and ongoing support throughout the US and international markets.